You are here

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
New reversal agent for factor Xa inhibitors shows promise

https://doi.org/10.1136/ebmed-2016-110390

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors KG and IJW have contributed to the literature and writing of this manuscripts.

    • Competing interests KG is a Co-Investigator in a prospective, open-label study of Andexanet-Alfa in patients receiving factor Xa inhibitors with acute major bleeding, sponsored by Portola Pharmaceuticals (NCT02329327). IJW is the Principal Investigator in a prospective, open-label study of Andexanet Alfa in patients receiving factor Xa inhibitors with acute major bleeding, sponsored by Portola Pharmaceuticals (NCT02329327) and has recently received grant support from CSL Behring and Terumo BCT.

    • Provenance and peer review Commissioned; internally peer reviewed.